September 21, 2020
Redox Biology
Uppsala University (Sweden)
“Conclusions: In this study, we demonstrated that NO can inhibit the replication of SARS-CoV-2 in Vero E6 and we identified the SARS-CoV-2 main protease as a target for NO. There is a great need for effective antivirals against SARS-CoV-2 to be used in the on-going COVID-19 pandemic. Based on this study and previous studies on SARS-CoV in vitro, and in a small clinical trial, we conclude that NO may be applied for clinical use in the treatment of COVID-19 and other human coronavirus infections.”
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
document
COVID-19,medical treatments